Disparities in the provision of next-generation sequencing (NGS) testing for advanced non-small cell lung cancer patients have been widely reported. However, it is unknown if NGS testing inequity is driven by differential care within the same practice or provider; and/or by the disproportionate share of historically marginalized patients receiving care at practices and/or providers with lower NGS testing rates overall. To comprehensively assess the total inequity in NGS testing for this patient population, researchers examined inequities within and across practice and providers.
Why this matters
The findings from this study can help researchers and policy-makers identify areas where policy interventions can be implemented to promote greater equity in access to NGS testing.